Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-CAD: Edoxaban Monotherapy vs Combination Therapy in AF and Stable CAD
NCT03718559Phase 4Completed
- Start
- May 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) and coronary artery disease (CAD) (2 arms). Primary endpoint: Rate of net Clinical Outcome at 1 year. Started May 2019; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03718559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718559.